ANTIANNEXIN-V MONOCLONAL ANTIBODY, PROCESS FOR PRODUCING THE SAME, AND USE THEROF

Using human annexin-V or human annexin-V plus dog annexin-V as antigen(s), hybridoma cell lines are prepared which are capable of producing anti-annexin-V monoclonal antibodies having a binding specificity to antigenic determinant site on annexin-V as antigenic protein and belonging to immunoglobuli...

Full description

Saved in:
Bibliographic Details
Main Authors KANEKO, NOBORU, MATSUDA, RYUKO, KAJITA,TADAHIRO, OHTA, YOHSUKE
Format Patent
LanguageEnglish
French
German
Published 24.05.2000
Edition7
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Using human annexin-V or human annexin-V plus dog annexin-V as antigen(s), hybridoma cell lines are prepared which are capable of producing anti-annexin-V monoclonal antibodies having a binding specificity to antigenic determinant site on annexin-V as antigenic protein and belonging to immunoglobulin G class. By the hybridoma cell lines are produced the anti-annexin-V monoclonal antibodies, with which a diagnostic agent is provided for diagnosis of myocardial infarction and angina pectoris. There is also provided diagnosis of myocardial infarction and angina pectoris using a first and a second monoclonal antibodies produced by the hybridoma cell lines to quantitate human annexin-V in a sample, in which an antigen-antibody reaction on annexin-V in the sample is caused with the first anti-annexin-V monoclonal antibody to form an annexin-V antigen/anti-annexin-V monoclonal antibody complex, the antigenic site of annexin-V of the formed annexin-V antigen/annexin-V monoclonal antibody complex is allowed to be bound with a labeled anti-annexin-V polyclonal or second monoclonal antibody so as to form a labeled form of said annexin-V antigen/anti-annexin-V monoclonal antibody complex bound with the polyclonal or the second monoclonal antibody, and the labeled form of the complex is quantitatively analyzed.
Bibliography:Application Number: EP19950936774